@article {Eftekhar249, author = {Zahra Eftekhar and Narges Izadi-Mood and Fariba Yarandi and Hadi Shojaei and Zahra Rezaei and Saeedeh Mohagheghi}, title = {Efficacy of Megestrol Acetate (Megace) in the Treatment of Patients With Early Endometrial Adenocarcinoma: Our Experiences With 21 Patients}, volume = {19}, number = {2}, pages = {249--252}, year = {2009}, doi = {10.1111/IGC.0b013e31819c5372}, publisher = {BMJ Specialist Journals}, abstract = {Background: There are therapeutic dilemmas regarding fertility-preserving treatment among young women with well-differentiated endometrial carcinoma.Materials and Methods: Twenty-one patients with stage IA well-differentiated endometrial adenocarcinoma were enrolled in a prospective study. The treatment initiated with 160 mg/d of megestrol acetate. The patients underwent dilatation and curettage and hysteroscopy after 3 months, and in cases of normal pathology, the therapy continued for another 3-month period. In patients who did not respond to treatment, the dosage of the drug was doubled (320 mg/d), and the therapy continued for another 3 months. At the second time, patients who did not respond to treatment were recommended for hysterectomy, and in patients who responded to treatment, an additional 3 months of treatment with megestrol acetate (320 mg/d) was administered.Results: Our results showed a response rate of 85.71\% (18 patients), and 3 patients underwent hysterectomy. The mean (SD) treatment duration was 8.85 (2.00) months (range, 6-12 months). The response to therapy was observed in 5 patients (27.78\%) with a dosage of 160 mg/d, and the remaining patients with 320 mg/d. Pregnancy occurred in 5 patients (27.78\%). Recurrence happened in 3 (16.67\%) of 18 patients who responded to treatment who did not give a permit to undergo hysterectomy and received medication again. Two (66.67\%) of these patients experienced remission again, whereas the other one was candidate for hysterectomy.Conclusions: The results of this study show that, when an initial response is not achieved or when disease recurs, use of 320 mg/d seems to be associated with a better therapeutic response. Furthermore, serious complications were not observed with this dosage.}, issn = {1048-891X}, URL = {https://ijgc.bmj.com/content/19/2/249}, eprint = {https://ijgc.bmj.com/content/19/2/249.full.pdf}, journal = {International Journal of Gynecologic Cancer} }